Name | Faldaprevir |
---|---|
Synonyms |
BI 201335
N-[(Cyclopentyloxy)carbonyl]-3-methyl-L-valyl-(4R)-4-({8-bromo-2-[2-(isobutyrylamino)-1,3-thiazol-4-yl]-7-methoxy-4-quinolinyl}oxy)-N-[(1R,2S)-1-carboxy-2-vinylcyclopropyl]-L-prolinamide Faldaprevir L-Prolinamide, N-[(cyclopentyloxy)carbonyl]-3-methyl-L-valyl-4-[[8-bromo-7-methoxy-2-[2-[(2-methyl-1-oxopropyl)amino]-4-thiazolyl]-4-quinolinyl]oxy]-N-[(1R,2S)-1-carboxy-2-ethenylcyclopropyl]-, (4R)- |
Description | Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection[1][2]. |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Molecular Formula | C40H49BrN6O9S |
Molecular Weight | 869.82 |
Exact Mass | 868.246521 |
LogP | 5.34 |
Index of Refraction | 1.647 |